Document is current

Article History

Received: 6 August 2024

Accepted: 9 December 2024

First Online: 31 December 2024

Declarations

:

: Not applicable.

: Not applicable.

: Athol U Wells reports consulting fees from Boehringer Ingelheim, Roche and Veracyte and speaker fees from Boehringer Ingelheim and Roche. Simon LF Walsh reports grants from Boehringer Ingelheim, Galapagos and the National Institute for Health and Research; consulting fees from Boehringer Ingelheim, CSL Behring, Galapagos, OncoArendi Therapeutics, the Open Source Imaging Consortium, Pliant, PureTech, Roche and Sanofi-Genzyme; speaker fees from Boehringer Ingelheim, Galapagos and Roche; he is the Chief Scientific Officer of Qureight. Ayodeji Adegunsoye reports grants from the National Institutes of Health (K23HL146942); consulting fees from Boehringer Ingelheim, Genentech/Roche and Inogen; and speaker fees from Boehringer Ingelheim. Vincent Cottin reports grants from Boehringer Ingelheim; consulting fees from Boehringer Ingelheim, Celgene/Bristol-Myers Squibb, CSL Behring, Ferrer, Galapagos, GlaxoSmithKline, Plaint, PureTech, Redx, Roche, Sanofi and Shionogi; speaker fees from Boehringer Ingelheim, Ferrer and Roche; support for attending meetings from Boehringer Ingelheim and Ferrer; and has participated on data safety monitoring boards/advisory boards for Celgene/Bristol-Myers Squibb, FibroGen, Galapagos, Galecto and Roche. Sonye K Danoff reports grants from Boehringer Ingelheim, Bristol-Myers Squibb and Genentech/Roche; royalties or licenses from UptoDate; consulting fees from Boehringer Ingelheim and Lupin Pharma; speaker fees from the France Foundation; support for travel from Boehringer Ingelheim; has participated on data safety monitoring boards/advisory boards for Galapagos and Galecto; and has leadership roles at the American Thoracic Society and Pulmonary Fibrosis Foundation. Anand Devaraj reports consulting fees from Brainomix, Boehringer Ingelheim, Roche, Astra Zeneca, GSK, Genentech, Pharmamar, and Vicore and stock options from Brainomix. Kevin R Flaherty reports grants paid to his institution from Boehringer Ingelheim; royalties or licences from UpToDate; and consulting fees from Arrowhead, AstraZeneca, Bellerophon, CSL Behring, Daewoong, DevPro, Dispersol, FibroGen, Horizon Therapeutics, Immunet, Insilico, Lupin, NeRRe Therapeutics, Pliant, Polarean, Pure Health, PureTech, Respivant, Roche/Genentech, Shionogi, Sun Pharmaceuticals, Trevi, United Therapeutics and Vicore. Peter M George reports personal fees from AstraZeneca, Avalyn, Brainomix, Boehringer Ingelheim, Cipla, Daiichi-Sankyo, GSK, Roche, Teva; grants from Boehringer Ingelheim and Roche; stock options from Brainomix. Kerri A Johannson reports grants paid to her institution from Three Lakes Foundation and University Hospital Foundation; consulting fees from Boehringer Ingelheim, Brainomix, Hoffman La Roche and Pliant Therapeutics; speaker fees from Abbvie and Boehringer Ingelheim; support for attending meetings from Boehringer Ingelheim; has participated on a data safety monitoring board for the PFOX trial; and stock or stock options from Thyron SAB. Martin Kolb reports research funding from Boehringer Ingelheim, Pieris and Roche; consulting fees from AbbVie, Algernon, Bellerophon, Boehringer Ingelheim, Cipla, CSL Behring, Horizon, LabCorp, Roche, ShouTi and United Therapeutics; speaker fees from Boehringer Ingelheim, Novartis and Roche; payment for expert testimony from Roche; has participated on data safety monitoring boards/advisory boards for LabCorp and United Therapeutics; and has a leadership role at the European Respiratory Journal. Yasuhiro Kondoh reports consulting fees from Asahi Kasei Pharma Corp, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd., Healios K.K., Janssen Pharmaceutical K.K., Shionogi & Co., Ltd. and Taiho Pharmaceutical Co.; and speaker fees from Asahi Kasei Pharma Corp, Bristol-Myers Squibb, Boehringer Ingelheim, Eisai Co., Janssen Pharmaceutical K.K., KYORIN Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma, NIPPON SHINYAKU CO., Ltd., Novartis Pharma KK, Shionogi & Co., Ltd. and Teijin Pharma Ltd. Andrew G Nicholson reports consulting fees from Galapagos, Medical Quantitative Image Analysis, Roche, Boehringer Ingelheim and payment for presentations from Boehringer Ingelheim and Up to Date. Sara Tomassetti reports consulting fees, speaker fees and support for attending meetings from Boehringer Ingelheim and Roche. Elizabeth R Volkmann reports payments made to her institution from Boehringer Ingelheim, Forbius, Horizon, Kadmon, the National Heart, Lung and Blood Institute, Prometheus; consulting fees from Boehringer Ingelheim, GlaxoSmithKline, Roche; speaker fees from Boehringer Ingelheim. Kevin K Brown reports grants from the National Heart, Lung and Blood Institute; consulting fees, speaker fees, support for attending meetings and participation on data safety monitoring boards/advisory boards from AbbVie, Biogen, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, CSL Behring, DevPro Biopharma, Dispersol, Eleven P15, Galapagos NV, Galecto, Huitai Biomedicine, Humanetics, the Open Source Imaging Consortium, Pliant, Redx Pharma, Sanofi, Third Pole, Translate Bio; and has leadership roles at the Fleischner Society and Open Source Imaging Consortium.